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Non-alcoholic fatty liver disease (NAFLD) is associated with increased cardiovascular disease (CVD) risk in children.
Non-high density lipoprotein-cholesterol (non-HDL-C) has been shown to be a good predictor of cardiovascular
events. Recent data in adults found non-alcoholic steatohepatitis (NASH) to be associated with significantly higher
levels of non–HDL-C than simple steatosis, suggestive it might be used as a non-invasive tool to diagnose NASH.
The goal of our study was to assess non-HDL-C levels in children with NAFLD. Our cohort consisted of pediatric
patients with biopsy-proven NAFLD. Anthropometric, laboratory, and histologic data were obtained on all patients.
Univariable analysis was performed to assess differences in clinical characteristics between groups. Spearman rank
correlation coefficients were calculated to assess the correlation between non-HDL-C levels and clinical variables.
ANCOVA was used to adjust for possible confounders. 302 subjects with NAFLD were included in our study; 203
with NASH and 99 without NASH. Subjects with NASH had significantly higher non-HDL-C levels than those without
(p = 0.004). Histologic features of NASH, including ballooning, inflammation, and fibrosis were found to be weakly
correlated with non-HDL-C levels, (p < 0.05 for all). After adjusting for the presence of metabolic syndrome
(MetS), ALT, and GGT, the association between non-HDL-C and NASH was not significant (p = 0.66). In Conclusion,
non-HDL-C levels are higher in children with NASH than those with simple steatosis, suggesting increased CVD risk.
This may be a reflection of the higher prevalence of MetS. Non-HDL-C had a positive association with histologic
features of NASH.
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The incidence of nonalcoholic fatty liver disease (NAFLD)
has been increasing dramatically over the past three de-
cades, which has been in parallel with the childhood
obesity epidemic. NAFLD is now the most common
cause of chronic liver disease in children and adolescents
(Schwimmer et al. 2006; Wieckowska and Feldstein 2005;
Chan et al. 2004). NAFLD encompasses a spectrum of
diseases that ranges from simple steatosis (characterized
by hepatic lipid accumulation) to non-alcoholic steato-
hepatitis (NASH) (characterized by evidence of lipid* Correspondence: alkhoun@ccf.org
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in any medium, provided the original work is paccumulation with associated hepatocyte inflammation,
injury, and varying degrees of fibrosis), which can pro-
gress to cirrhosis and even end-stage liver disease (Vajro
et al. 2012; Feldstein et al. 2009). Multiple studies are
suggesting that NAFLD may be the hepatic manifest-
ation of metabolic syndrome (MetS) (Abdelmalek and
Diehl 2007; Pagano et al. 2002). There appears to be a
strong association between NAFLD, MetS, and insulin
resistance, which has brought into question the possibil-
ity of NAFLD playing a role in cardiovascular disease
(CVD). Furthermore, recent evidence has now linked
NAFLD with an increased prevalence of CVD, inde-
pendent of the presence of MetS or traditional risk fac-
tors (Alkhouri et al. 2011; Targher 2007; Targher et al.
2008a). More importantly, it has also been found that
children with NASH can be at an even higher risk foran Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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(Nobili et al. 2010).
Recently, non-high-density lipoprotein cholesterol (non-
HDL-C) has become increasingly recognized as an im-
portant measure of atherogenic particles, as it reflects the
cholesterol in all lipoprotein particles that are considered
to be atherogenic. Non-HDL-C has been strongly associ-
ated with predicting coronary artery disease (Orakzai et al.
2009). In adults, it has been added on to a recommended
screening algorithm by The Adult Treatment Panel III of
the National Cholesterol Education Program (Grundy
et al. 2004). Additionally, in a consensus report by the
American Diabetes Association and American College of
Cardiology Foundation, they identified that non-HDL-C
was a better marker than low-density lipoprotein (LDL)
cholesterol for identifying high-risk patients at cardiovas-
cular risk (Brunzell et al. 2008).
Taking into consideration that patients with NAFLD
are at increased cardiovascular risk, and that those
patients with NASH may be at even higher risk for ath-
erosclerosis than those with simple steatosis, a recent
adult study investigated the ability of non-HDL-C to dif-
ferentiate NASH from simple steatosis in patients with
NAFLD. In those patients who did not take any lipid-
lowering agents, NASH was associated with significantly
higher levels of non-HDL-C as compared to those pa-
tients with just simple steatosis. Their study concluded
that non-HDL-C could be utilized as a non-invasive bio-
marker to differentiate between steatosis and NASH
(Corey et al. 2012). In our study we aimed to examine
non-HDL-C levels in pediatric patients with NAFLD to
assess if increased CVD risk may be associated with
worsening histologic severity of NAFLD, and more spe-
cifically NASH as compared to simple steatosis.
Materials and methods
Patients
Pediatric patients with biopsy-proven NAFLD were seen
at and enrolled in this study performed at the Bambino
Gesù Children’s Hospital (Rome, Italy) between January
2003 and December 2009. This study was approved by
the ethics committee of the Bambino Gesù Children’s
Hospital and Research Institute. The study was carefully
explained to the children’s guardians and written con-
sent was obtained.
All included subjects raised suspicion for NAFLD
based on persistently elevated serum aminotransferase
levels and imaging studies that revealed a diffusely hypere-
chogenic liver suggestive of fatty liver, with a final diagno-
sis of NAFLD made on liver biopsy. Exclusion criteria for
these patients with NAFLD including (1) alcohol con-
sumption; (2) hepatic viral infections (such as hepatitis A,
B, C, D, and E; cytomegalovirus; and Epstein-Barr virus);
(3) history of parenteral nutrition; (4) use of drugs that areknown to induce steatosis (e.g.: prednisone, valproate, or
amiodarone), affect body weight or carbohydrate metabol-
ism; and (5) known liver disease, such as autoimmune
liver disease, metabolic liver disease, alpha-1-antitrypsin
associated liver disease, and Wilson’s disease. These were
ruled out using standard clinical, laboratory, and histo-
logical criteria.
Anthropometric data
Clinical variables were recorded, which included standard
procedures for height and weight (Lohman et al. 1988).
The body mass index (BMI) and its standard deviation
score (Z score) were calculated (Kuczmarski et al. 2000).
Obesity was defined by a BMI greater than or equal to
95th percentile adjusted for age and sex. Waist circum-
ference was also measured, which was evaluated at the
highest point of the iliac crest with a standing subject
(Li et al. 2006). Waist circumference to height ratio was
also calculated.
MetS in this cohort was defined as having three or
more of the following five criteria: (1) abdominal obesity,
defined as waist circumference (WC) ≥ 90th percentile
for age (Fernandez et al. 2004); (2) low HDL-cholesterol,
defined as concentrations <5th percentile for age and sex
(American Academy of Pediatrics 1992); (3) hypertriglyc-
eridemia, defined as triglyceride (TG) level >95th percent-
ile for age and sex (American Academy of Pediatrics
1992); (4) hypertension, defined as systolic or diastolic
blood pressure >95th percentile for age and sex (Report of
the Second Task Force on Blood Pressure Control in Chil-
dren 1987); and (5) impaired fasting glucose (≥110 mg/
dL), impaired glucose tolerance or known type 2 diabetes
mellitus (Genuth et al. 2003).
Laboratory assessment
Laboratory data collection included total cholesterol
(TC), HDL cholesterol, triglycerides, aspartate amino-
transferase (AST), alanine aminotransferase (ALT),
serum γ-glutamyltransferase (GGT), total bilirubin, al-
bumin, and INR. These were obtained and measured
by standard laboratory methods. The non-HDL-C was
calculated from the total cholesterol subtracted by the
HDL cholesterol (non-HDL-C = TC – HDL). The homeo-
stasis model assessment of insulin resistance (HOMA-IR)
(Matthews et al. 1985) was calculated as markers for insu-
lin sensitivity. None of the patients were on lipid-lowering
medications at the time of the lipid profile measurements.
Liver histology
Liver biopsy was performed in all subjects because of
the clinical indication to either assess the presence of
NASH, degree of fibrosis, and/or to identify if other liver
diseases were present. After an overnight fast, liver biopsy
was performed under general anesthesia and ultrasound








Male 68 (33.5) 42 (42.4) 0.13
Age at first visit (y) 12.3 ± 3.1 12.3 ± 3.1 0.98
Obese 188 (92.6) 80 (80.8) 0.002
BMI (kg/m2) 26.3 ± 4.2 25.5 ± 3.7 0.11
BMI percentile 97.0 [94.0, 98.0] 96.0 [92.0, 98.0] 0.12
Waist circumference
(cm)
91.7 ± 11.4 89.1 ± 9.5 0.044
WC percentile 97.0 [90.0, 97.0] 90.0 [89.0, 97.0] <0.001
WC/Height ratio 0.60 ± 0.04 0.58 ± 0.04 <0.001
Total cholesterol
(mg/dL)
163.5 ± 32.6 149.2 ± 25.3 <0.001
HDL (mg/dL) 53.0 [39.0, 69.0] 56.0 [38.0, 71.0] 0.96
Non-HDL cholesterol
(mg/dL)
105.8 ± 40.2 92.3 ± 32.8 0.004
Triglycerides (mg/dL) 114.0 ± 62.9 84.6 ± 41.8 <0.001
Hypercholesterolemia 121 (59.6) 41 (41.4) 0.003
Hypertriglyceridemia 136 (67.0) 52 (52.5) 0.015
Hypertension 55 (27.1) 29 (29.3) 0.69
HOMA-IR 2.7 ± 1.7 2.6 ± 2.0 0.83
IGT/Diabetes 88 (43.3) 45 (45.5) 0.73
Metabolic syndrome 131 (64.5) 37 (37.4) <0.001
ALT (U/L) 73.0 [50.0, 99.0] 70.0 [50.0, 89.0] 0.41
AST (U/L) 57.5 ± 29.3 49.9 ± 16.3 0.017
GGT (U/L) 27.0 [20.0, 40.0] 25.0 [17.0, 33.0] 0.031
Total bilirubin
(mg/dL)
0.65 ± 0.24 0.73 ± 0.22 0.007
Albumin (g/dL) 4.6 ± 0.53 4.6 ± 0.73 0.64
Values presented as Mean ± SD with t-test; Median [P25, P75] with Wilcoxon
rank sum test, or N (%) with Pearson’s chi-square test.
P-values in bold are statistically significant.
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needle (Biopince, Amedic, Sweden). The Sonoline Omnia
ultrasound machine (Siemens, Munich, Germany) was
used, which is equipped with a 5-MHz probe (5.0 C 50,
Siemens) and biopsy adaptor. For each subject, two biopsy
passes in different liver segments were made, and the
length of the liver specimen was recorded in millimeters.
Only samples that included at least 5–6 complete portal
tracts and with a length of ≥ 15 mm (Poynard et al. 2007)
met the requirements for this study. Biopsies were rou-
tinely processed and staining of liver tissue included
hematoxylin-eosin, Periodic acid-Schiff diastase, Van Gie-
son, and Prussian blue stain. A single hepatopathologist
reviewed the biopsies and was blinded to the clinical and
laboratory data.
Biopsies were evaluated by a single expert pediatric
hepatopathologist who established the histopathological
diagnosis of NASH. Based on this categorization patients
were divided into two groups: 1) “NASH” or 2) diagnosis
not compatible with NASH or “not NASH”. Liver hist-
ology was scored using the NAFLD activity scoring (NAS)
system developed by the NASH Clinical Research Net-
work (Kleiner et al. 2005). The grade of steatosis (0 – 3),
hepatocyte ballooning (0 – 2), and lobular inflammation
(0 – 3) were totaled to determine the NAS (0 – 8) score.
Portal inflammation (PI) was graded from 0 to 2 (0 = no
PI, 1 =mild PI, and 2 =more than mild PI). Mild PI was
defined as a few mononuclear cells, usually in more than
one portal tract. More than mild PI was defined as at least
one portal area showing moderate to marked density of
inflammation, and/or the presence of lymphoid aggre-
gates. Fibrosis was staged as the following: 0 = no fibro-
sis, 1 = periportal or perisinusoidal, 2 = perisinusoidal
and portal/periportal fibrosis, 3 = bridging fibrosis, and
4 = cirrhosis.
Statistical analysis
Descriptive statistics were performed for all variables. Cat-
egorical variables were presented as frequencies and per-
centages. Continuous variables were presented as mean ±
standard deviation or median [25th, 75 percentiles]. Uni-
variable analysis was performed to assess differences be-
tween subjects with and without NASH. Student’s t-tests
or the non-parametric Wilcoxan rank sum tests were used
to compare continuous or ordinal variables. Pearson’s chi-
square tests were used for categorical factors. Spearman
rank correlation coefficients (rho) were calculated to as-
sess the correlation between non-HDL cholesterol levels
and liver histology features (steatosis, ballooning, inflam-
mation, and degree of fibrosis) and clinical characteristics.
Analysis of covariance (ANCOVA) was used to adjust for
possible confounders. All demographic and clinical factors
were considered for inclusion in the model, and an auto-
mated stepwise variable selection was performed on 1,000bootstrap samples to choose the final model. Variables
with inclusion rates of at least 50% were included in the
model. A p < 0.05 was considered statistically significant.
All analyses were performed using SAS (version 9.2, The
SAS Institute, Cary, NC) and R (version 2.13.1, The R
Foundation for Statistical Computing, Vienna, Austria).
Results
Demographic and clinical characteristics
Three hundred and two children with biopsy-proven
NAFLD were included in this study. Table 1 summarizes
the anthropometric, clinical and laboratory data. There
were 203 subjects with biopsy proven NASH (67.2%)
and 99 subjects without NASH (32.8%). Of the total sub-
jects, 36.4% were male, 63.6% were female. The mean
age at initial visit for this study was 12.3 ± 3.1 years. Two
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be obese. One hundred and sixty-eight (55.6%) children
were found to have MetS. Univariable analysis was per-
formed, which showed that obesity, greater WC, hyper-
cholesterolemia, hypertriglyceridemia, MetS, and higher
non-HDL cholesterol were significantly associated with
NASH. Total cholesterol and triglyceride levels were
significantly higher in NASH patients; whereas, HDL-C
levels were similar in the two groups. In addition, AST,
GGT, and lower total bilirubin were also significantly as-
sociated with NASH.
Liver biopsy findings
Histologic features for subjects are represented in Table 2.
As expected, subjects with NASH had higher NAS scores
than those without. Majority of subjects with NASH had
mild (134 subjects; 66%) or more than mild (21 subjects;
10.3%) portal inflammation, and ballooning was present in







<5% 0 (0.0) 2 (2.0)
5-33% 34 (16.7) 68 (68.7)
34-65% 85 (41.9) 26 (26.3)
> = 66% 84 (41.4) 3 (3.0)
Lobular inflammation <0.001
None 5 (2.5) 19 (19.2)
<2 under 20× 147 (72.4) 80 (80.8)
2–4 under 20× 48 (23.6) 0 (0.0)
>4 under 20× 3 (1.5) 0 (0.0)
Portal inflammation <0.001
None 48 (23.6) 55 (55.6)
Mild 134 (66.0) 43 (43.4)
More than mild 21 (10.3) 1 (1.0)
Ballooning* <0.001
None 66 (32.8) 94 (94.9)
Few 55 (27.4) 5 (5.1)
Many 80 (39.8) 0 (0.0)
Fibrosis <0.001
0 33 (16.3) 75 (75.8)
1 137 (67.5) 18 (18.2)
2 15 (7.4) 4 (4.0)
3 18 (8.9) 2 (2.0)
NAS* 4.5 ± 1.4 2.2 ± 0.65 <0.001
*Data not available for all subjects. Missing values: Ballooning = 2, NAS = 2.
Values presented as Mean ± SD with t-test or N (%) with Wilcoxon rank
sum tests.
P-values in bold are statistically significant.some degree of fibrosis was noted in majority of patients:
mild fibrosis (grade 1) in 137 patients (67.5%); moderate
fibrosis (grade 2) in 15 patients (7.4%); and advanced fi-
brosis (grade 3) in 18 patients (8.9%). None of these pa-
tients had liver cirrhosis. The mean NAS score in patients
with NASH was 4.5 ± 1.4. In those patients without
NASH, NAS was 2.2 ± 0.65, p <0.001.
Non-HDL-C levels were higher in the NASH cohort and
had positive correlation with histological features
Subjects with NASH were found to have significantly
higher non-HDL-C levels than those without NASH
(105.8 ± 40.2 versus 92.3 ± 32.8; p = 0.004) (Figure 1). Im-
portantly, histologic features of pediatric NASH including
lobular inflammation, portal inflammation, and ballooning
had a positive correlation with non-HDL-C levels that
was statistically significant (p = 0.005, p = 0.001, p = 0.01
respectively), and the NAS score was significantly asso-
ciated with non-HDL-C (p = 0.024) as shown in Table 3.
Moreover, fibrosis was also found to be positively corre-
lated to non-HDL-C levels (Spearman’s rho of 0.25, 95%
CI: 0.14, 0.36; p <0.001). The grade of steatosis, on the
other hand, was not significantly associated with non-
HDL-C. The association between non-HDL-C level and
the histologic diagnosis of NASH was not significant
after adjusting for MetS, WC/Height ratio, GGT and
ALT in the multivariable analysis (Figure 2) (adjusted
mean (95% CI): 102 (97.4, 106.6) vs 100.1 (93.4, 106.9);
p = 0.66) implicating that other factors known to be as-
sociated with increased cardiovascular risk may explain
the association noted in the univariable analysis.
Discussion
In this large study of pediatric patients with biopsy-
proven NAFLD, our main findings have demonstrated
that (1) non-HDL-C levels were higher in children with
biopsy proven NASH as compared to children with sim-
ple steatosis and (2) histologic features of NASH, such
as ballooning, lobular inflammation, portal inflammation
and fibrosis were found to be correlated with non-HDL-C
levels. This data has further extended the knowledge base
of the cardiovascular complications of NASH in the
pediatric population with NAFLD. The higher-non-HDL-
C levels found in this study adds to prior studies that have
shown an increased risk of CVD in patients with NASH.
Interestingly, on multivariable analysis this finding did not
hold when adjusting for MetS, WC/Height ratio (a meas-
ure of central obesity and associated with MetS) (Bener
et al. 2013), GGT, and ALT. Given the lack of a significant
difference of non-HDL-C in those patients with and with-
out NASH on multivariable analysis, our study does not
support non-HDL-C as a single biomarker for NASH.
The etiology of this finding on multivariable analysis re-
mains unclear, and while it may be more of a reflection of
Figure 1 Unadjusted non-HDL cholesterol levels.
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likely component of increased hepatic inflammation given
the role that GGT and ALT have in this study’s multivari-
able analysis.
Studies in both adults and children have shown an asso-
ciation between NAFLD and CVD (Alkhouri et al. 2011;
Targher 2007; Schwimmer et al. 2008). In one case control
study of 150 overweight children with biopsy proven
NAFLD versus those without, NAFLD was found to be
strongly associated with risk factors for cardiovascular dis-
ease, including higher glucose, insulin, blood pressure, TC,
LDL, triglyceride, and lower HDL. Furthermore, obese
children with NAFLD were significantly more likely to
have metabolic syndrome as compared to obese children
without NAFLD (Schwimmer et al. 2008). Various adultTable 3 Correlations between non-HDL cholesterol levels
and histologic features
Factor Spearman’s rho 95% CI p-value
Steatosis 0.02 (−0.09, 0.13) 0.71
Lobular inflammation 0.16 (0.05, 0.27) 0.005
Portal inflammation 0.19 (0.07, 0.30) 0.001
Ballooning 0.15 (0.04, 0.26) 0.01
Fibrosis 0.25 (0.14, 0.36) <0.001
NAS 0.13 (0.02, 0.24) 0.024
rho: correlation coefficient; CI: confidence interval.studies have also looked at diagnostic markers for early
atherosclerosis, which has included findings of a signifi-
cant increase in carotid intima-media thickness (CIMT) in
patients with NAFLD (Brea et al. 2005), with some CIMT
studies even suggesting NAFLD to be an independent risk
factor for developing atherosclerosis (Mohammadi et al.
2011; Li et al. 2012). Interestingly, while one pediatric
study did not show CIMT to be associated with NAFLD
in children (Manco et al. 2010), a recent pediatric study in
2012 showed CIMT to be significantly higher in patients
with NAFLD as compared to obese and normal controls
(Gokce et al. 2013). Other studies have also found im-
paired endothelial function and increased arterial stiff-
ness in patients with NAFLD (Vlachopoulos et al. 2010;
Villanova et al. 2005).
There continues to be a growing body of evidence that
has shown an increased prevalence of CVD risk in pa-
tients with NAFLD, with additional studies showing that
it can be independent of the presence of MetS or trad-
itional risk factors (Alkhouri et al. 2011; Targher 2007;
Targher et al. 2008a). A recent adult study found lipid
ratios to be significantly associated with NAFLD, with a
stepwise statistically significant difference between pa-
tients who had normal biopsies versus simple steatosis
versus NASH. But more interestingly, the histologic se-
verity of inflammation and liver injury appeared to be
strongly associated with a more atherogenic lipid profile
Figure 2 Adjusted non-HDL cholesterol levels.
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genic risk of NAFLD can be found not only in the adult
population, but also in the pediatric population, with in-
creased risk with progression of disease. A prior pediatric
study from our institution evaluated 118 consecutive chil-
dren with biopsy-proven NAFLD and found that the se-
verity of liver injury and fibrosis was strongly associated
with certain markers of atherogenic risk, in particular,
ratios of cholesterol ester-rich lipoproteins such as TC/
HDL, LDL/HDL, and TG/HDL. These lipid ratios were
found to have a significant positive correlation with the
NAFLD activity and fibrosis scores, with also a significant
difference found between those with definitive NASH as
compared to those with simple steatosis or borderline
diagnosis. Additionally, this association was found to be
independent of the presence of MetS, insulin resistance,
and obesity (Nobili et al. 2010). In our current study we
investigated CVD risk in obese children through non-
HDL-C levels, which were found to be significantly
higher in children with biopsy proven NASH as com-
pared to those with simple steatosis. In addition, histo-
logic features of NASH were also found to be correlated
with non-HDL-C levels.
Potential biological mechanisms for a higher risk for
atherosclerosis in NAFLD have been described, which
includes increased systemic inflammation and oxidative
stress. Markers, such as C-reactive protein (CRP) andfibrinogen levels, which are known to be inflammatory
markers, are increased in patients with NAFLD, and
particularly in those with NASH (Yoneda et al. 2007;
Targher et al. 2008b). In our study, the significant differ-
ence of non-HDL-C in those patients with NASH versus
simple steatosis highlights the cardiovascular implica-
tions of NASH. But in addition, the positive correlation
of non-HDL-C levels with histologic scores of balloon-
ing, inflammation, and fibrosis in NASH speaks towards
the potential relationship between severity of hepatic
damage and an atherogenic lipid profile.
Hepatic inflammation in it of itself is thought to be
atherogenic, as studies have found a strong association
between CVD and elevated ALT and GGT, which are
surrogate markers of inflammation (Schindhelm et al.
2007; Lee et al. 2007; Ioannou et al. 2006). Recent ani-
mal studies have also suggested that hepatic insulin re-
sistance and hepatic inflammation can also contribute to
the development of dyslipidemia and increased cardio-
vascular disease risk (Guillen et al. 2008; Biddinger et al.
2008). In our study, the significance of non-HDL-C as a
distinguishing marker for NASH on multivariate analysis
was lost when controlling for such serum markers as
GGT and ALT, which themselves are markers of inflam-
mation and associated with cardiovascular risk.
It is also hypothesized that alterations in lipid metabol-
ism may influence the development of steatosis versus
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very low density lipoprotein (VLDL) and triglyceride
production in the development of MetS and NASH
(Choi and Ginsberg 2011; Choi and Diehl 2008; Fujita
et al. 2009; Adiels et al. 2008). It is additionally thought
that alterations in the exportation of triglycerides (pack-
aged as VLDL and intermediate density lipoprotein
(IDL)) may influence hepatic lipid storage and the de-
velopment of NAFLD (Fujita et al. 2009; Choi et al.
2007; Yamaguchi et al. 2007). Unfortunately, direct mea-
sures of VLDL and IDL are not readily available to clini-
cians and are expensive. However, non-HDL-C is an
indirect measure that encompasses both VLDL and IDL
along with other lipoproteins, which include LDL, lipo-
protein A, and chylomicrons. Our findings in this study
may indirectly highlight the potential influence that
VLDL and IDL may have on development of steatosis
versus NASH.
The main strength of this study is the inclusion of a
large group of over 300 children with biopsy-proven
NAFLD that includes a full spectrum of the disease and
varying degrees of fibrosis. None of the children in the
current study were on lipid lower agents at the time of
lipid measurement. In addition, there was an extensive
characterization of anthropometric, metabolic, and
histologic profile of these patients. To our knowledge,
this is the first pediatric study to look at non-HDL-C in
patients with NAFLD. However, this study has some
limitations, which includes the fact that our patients
were seen at a large referral tertiary care medical center,
with a majority of our NAFLD patients having biopsy-
proven NASH and a high prevalence rate of fibrosis.
These findings therefore may not be generalizable to the
pediatric population in the community. In addition, the
majority of children were of Caucasian descent, thus the
association between NAFLD and non-HDL-C may be
different among other ethnicities. Lastly, this study is a
cross-sectional study, thus it only showed an association
between the severity of NAFLD and non-HDL-C, and
thus could not infer causation.
In conclusion, non-HDL-C levels were found to be
higher in children with NASH as compared to those
with simple steatosis, suggestive of an increased risk for
CVD. This may be more of a reflection of an increased
prevalence of MetS in this population, but the increased
hepatic inflammation of NASH may have played a role
in the finding. Histologic features of NASH, such as bal-
looning, inflammation, and fibrosis were found to be
correlated with non-HDL-C levels. Together, this con-
tinues to highlight again the association of NASH with
increased CVD risk. Future studies would be beneficial
to further evaluate the role of non-HDL-C and its
association with increased CVD risk in children with
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